Sweden’s MedVasc Secures €2.2M To Advance Anesthesia Catheter Toward U.S. Approval

”The strong participation from current owners demonstrates continued confidence in MedVasc’s strategy execution capability, and long-term value creation. The board and management view this support as a clear validation of the company’s direction and its ongoing development efforts” says Cathrin Johansson CEO of MedVasc.

Analysis from 2025–2026 points to sustained funding momentum across European MedTech and adjacent HealthTech sectors providing context for MedVasc’s shareholder backed raise.

Larger later-stage rounds include ProVerum in Ireland, which raised €68.6 million for minimally invasive urology treatments, and SamanTree Medical in Belgium, which secured €20 million from the European Investment Bank for real-time surgical imaging.

Mid-sized financings saw ShanX Medtech in the Netherlands raise a combined €24 million to tackle antimicrobial resistance while Austria’s PIUR IMAGING raised €5.6 million to scale its 3D ultrasound platform.

Read Also - After Raising Nearly €60M In 2025, London’s Sokin Secures An Additional €83M For Its Payments Platform

At the earlier stage Ahead Health in Switzerland secured €5.1 million for preventive healthcare services and Poland’s Doctor.One raised €4 million to expand its chronic care model.

MedVasc AB was founded in 2013 by Michael Åkesson, a senior interventional radiology consultant with over 20 years of experience in catheter-based treatments and diagnostics. Previously, he led the Division of Endovascular Surgery at the Vascular Department, University Hospital SUS Malmö, and now serves as a senior consultant at the Scandinavian Venous Centre in Malmö.

MedVasc is participating in SmiLe’s incubator programme in Lund, a venture hub supporting life science and FoodTech startups from concept to commercialisation. SmiLe’s flagship incubator has supported over 110 startups, raising more than €1.05 billion in venture capital and contributing to 21 successful IPOs.

The company has developed and patented Solutio, a medical device designed to improve anaesthetic procedures for varicose vein treatments. Solutio enables safe, precise, and painless local anesthesia during minimally invasive vascular procedures, including thermal ablation treatments, compatible with global gold-standard RF and laser fibers. It provides clinicians enhanced control and patient comfort when treating chronic venous disorders.

With the recently secured financing, MedVasc is well positioned to accelerate the remaining steps toward FDA clearance for Solutio in the U.S., with market approval expected in autumn 2026.

About MedVasc

MedVasc has developed and patented Solutio™, a medical device designed to improve anesthesia during varicose vein treatments. The catheter enables painless, precise local anesthesia for minimally invasive procedures. Currently for investigational use only Solutio™ has not been evaluated by the FDA and is not yet available for sale in the U.S.